LOXL1 and prostate carcinoma: LOXL1‐AS1, which researched in this study, has been reported to regulate prostate cancer cell cycle through sponging miR‐541‐3p and targeting CCND1.18 Moreover, it was also found to predict a poor prognosis and promote cell proliferation and metastasis in osteosarcoma.19 Nonetheless, its role in LUAD remains extremely unclear.